Targeted & light-guided approaches

The therapeutic potential of PCP relies on the activation of platelet alpha-granules. Upon activation, these granules undergo exocytosis, releasing a vast array of bioactive proteins, including Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), and Transforming Growth Factor-Beta (TGF-beta). These growth factors bind to specific tyrosine kinase receptors on target cell membranes, initiating intracellular signaling cascades that drive cell migration, mitogenesis, and angiogenesis, thereby accelerating localized tissue healing and soft tissue regeneration.

Beyond regenerative medicine, peer-reviewed scientific literature has linked platelet physiology directly to neurodevelopmental disorders, specifically Autism Spectrum Disorder (ASD). Platelets serve as a highly accurate peripheral biomarker and cellular model for central nervous system neurons. Both cell types share overlapping gene expression profiles and contain similar types of dense granules loaded with partially the same signaling molecules, such as serotonin (5-hydroxytryptamine, or 5-HT) and adenosine triphosphate (ATP).

Clinical studies have consistently shown that a significant subset of individuals with ASD exhibit hyperserotonemia—elevated serotonin levels in whole blood and platelet-rich plasma—often driven by increased density of the serotonin transporter (SERT) and altered dense granule morphology. By modulating systemic inflammatory markers and utilizing the neuro-mimetic properties of concentrated autologous platelets, PCP therapy is being actively explored in academic research to support cellular-level signaling and metabolic stabilization in neurodevelopmental conditions.

In healthy tissues, cells process glucose primarily through mitochondrial oxidative phosphorylation, a highly efficient process that requires oxygen. However, cancer cells undergo a profound metabolic shift known as the Warburg Effect. Even in the presence of abundant oxygen, cancer cells dramatically upregulate glucose transporters (such as GLUT1) and key glycolytic enzymes (such as Hexokinase 2) to ferment glucose into lactate at an extremely high rate. This inefficient process consumes up to 20 times more glucose than normal cells, providing cancer cells with the rapid energy and cellular building blocks they need to multiply and expand.

The Cancer Glycolysis Blockade utilizes specific, non-toxic glucose analogs and metabolic blockers, such as 2-Deoxy-D-Glucose (2-DG). These inhibitors work via competitive inhibition:

1. GLUT Transporter Blockade: The inhibitor is taken up by the cancer cell's highly active glucose transporters, blocking actual glucose from entering.
2. Hexokinase Inhibition: Inside the cell, the analog is phosphorylated by hexokinase but cannot be processed further. The trapped, phosphorylated product inhibits hexokinase and stalls the glycolytic pathway.
3. ATP Starvation and Apoptosis: Deprived of glucose, the cancer cell can experience ATP depletion, oxidative stress, and mitochondrial dysfunction, which may activate apoptotic pathways and lead to cell death. Many normal cells tolerate reduced glucose better by drawing on alternative fuels such as fatty acids and ketone bodies, which is the proposed basis for the selectivity.

Conventional chemotherapy drugs are very small molecules. When injected into the bloodstream, they distribute rapidly and non-selectively throughout the entire body, penetrating healthy tissues and organs, which leads to severe side effects like kidney damage, nerve damage, and intense nausea. SMA CDDP overcomes this through a process known as the Enhanced Permeability and Retention (EPR) effect:

• Tumor Vascular Permeability: To support their rapid growth, tumors quickly build new blood vessels. These vessels are poorly constructed and highly defective, featuring large gaps (fenestrations) in their endothelial lining.
• Macromolecular Accumulation: SMA CDDP is a very large macromolecule. Because of its large size, it largely cannot cross the tight blood vessels of healthy tissues, which helps limit exposure of normal organs. However, when it reaches the tumor, it easily slips through the large gaps in the defective tumor blood vessels, accumulating directly in the cancer tissue.
• Defective Lymphatic Drainage: Tumors also lack functional lymphatic drainage systems. Once SMA CDDP enters the tumor mass, it cannot be cleared away, trapping the drug within the cancer tissue for an extended period. Over time, the chemical bond between the SMA copolymer and the cisplatin slowly breaks down, releasing active cisplatin directly into the tumor. This is intended to deliver a sustained, locally concentrated dose of chemotherapy within the tumor while keeping systemic exposure comparatively low.

The proposed selectivity of IR-783 Photoimmunotherapy relies on a dual mechanism:

• Selective Tumor Accumulation: IR-783 is a heptamethine cyanine dye that possesses a unique chemical structure. It is actively transported into cancer cells through overexpressed cell-surface transporters, such as Organic Anion Transporting Polypeptides (OATPs), which are highly active in malignant cells but virtually absent in healthy tissues. Once inside, the dye targets and accumulates directly within the cancer cell's mitochondria and lysosomes.
• Photothermal and Photodynamic Activation: When the tumor is exposed to near-infrared laser light (typically at an 808 nm wavelength, which easily penetrates deep into tissues without harming the skin):

1. Mitochondrial Collapse: The dye absorbs the laser light and converts it into intense localized thermal energy (photothermal effect), raising the temperature inside the cancer cell's mitochondria, causing them to rupture and halting all energy production.
2. Reactive Oxygen Generation: The activation also generates highly reactive singlet oxygen and free radicals (photodynamic effect) that destroy the cell membrane from within, causing rapid cell death.
3. Immunogenic Cell Death: As the cancer cells rupture, they release intact tumor antigens and inflammatory signals directly into the surrounding tissue. This immediately recruits and activates local dendritic cells and natural killer (NK) cells, triggering a powerful, systemic immune attack against any remaining cancer cells.

Unlike light-based therapies (such as Photodynamic Therapy), which have very limited tissue penetration, low-intensity ultrasound can safely reach deep organs and bone structures. The treatment works through a three-step biophysical mechanism:

1. Selective Sensitization: The patient receives a non-toxic sonosensitizing agent (such as 5-ALA), which is selectively absorbed and retained by cancer cells due to their highly active metabolism.
2. Acoustic Cavitation: Low-intensity ultrasound is directed at the targeted tumor area, triggering ultrasound cavitation—the rapid formation, growth, and energetic collapse of microscopic bubbles within the cellular fluid.
3. Selective Cell Necrosis: The collapse of these microbubbles generates localized physical shock waves, microstreaming, and microscopic light emissions. This is thought to activate the sonosensitizer within sensitized cancer cells, generating singlet oxygen and free radicals that damage cell membranes and cause cell death, while the preferential uptake of the sensitizer is intended to spare surrounding healthy tissue.